title: Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy.
abstract: Somatostatin receptors (SSTRs) already act as important roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high expression levels for prognosis predicting and octreotide LAR treatment purposes but less noticed in gastrointestinal stromal tumors (GISTs). Our study aims to fully evaluate the expression levels and prognostic values of SSTRs in GIST patients. For SSTRs expression detection, qPCR were used in 25 fresh GIST specimens, and then, 453 GIST samples (405 GISTs with operation only and 48 with imatinib adjuvant therapy after surgery) were collected for tissue microarrays (TMAs) construction and confirmed by immunohistochemistry (IHC). Clinicopathological data were confirmed by pathological diagnosis and clinical recorders, recurrence-free survivals (RFS) were evaluated in 453 GIST patients. With IHC performed, SSTR1 and SSTR2 present high positive proportion (81.9% and 87.6%) in 453 GISTs in our study, and positive expression rates of SSTR3, SSTR4 and SSTR5 are 56.1%, 8.8% and 47.2%, respectively. SSTR2 and SSTR5 negative expression are associated with decreased RFS when compared to positive cases by Kaplan-Meier survival analyses with log-rank test and univariate analysis in GISTs, furthermore, SSTR2 was an independent prognostic indicator for GISTs by multivariate analysis. In our study, detection of SSRT2 and SSTR5 expression helps to predict different prognosis in GIST patients. SSTR2 is a novel independent prognostic biomarker for GISTs. With high expression performance of SSTRs in GISTs, new therapeutic strategies such as octreotide or pasireotide LAR could be taken into consideration in selected advanced GIST patients.
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Wen-Yi
authors: WY
authors: Zhao
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Chun
authors: C
authors: Zhuang
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Jia
authors: J
authors: Xu
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Ming
authors: M
authors: Wang
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Zi-Zhen
authors: ZZ
authors: Zhang
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Lin
authors: L
authors: Tu
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Chao-Jie
authors: CJ
authors: Wang
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Tian-Long
authors: TL
authors: Ling
authors: Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Hui
authors: H
authors: Cao
authors: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, PR China.
authors: Zhi-Gang
authors: ZG
authors: Zhang
keywords: Gastrointestinal stromal tumor; octreotide; pasireotide; prognosis; somatostatin receptor
references: Cancer Epidemiol. 2011 Dec;35(6):515-20
references: 21489899
references: Cancer Cell Int. 2013 Sep 23;13(1):93
references: 24059654
references: Hum Pathol. 2008 Oct;39(10):1411-9
references: 18774375
references: Lancet Oncol. 2012 Mar;13(3):265-74
references: 22153892
references: Ann Oncol. 2006 Mar;17(3):461-6
references: 16364959
references: Front Neuroendocrinol. 2013 Aug;34(3):228-52
references: 23872332
references: Acta Oncol. 2013 May;52(4):783-92
references: 23116418
references: APMIS. 2009 Feb;117(2):73-86
references: 19239429
references: J Clin Oncol. 2005 Aug 20;23(24):5795-804
references: 16110036
references: BMC Cancer. 2007 Dec 20;7:230
references: 18096058
references: J Clin Oncol. 2009 Oct 1;27(28):4656-63
references: 19704057
references: Cancer. 2002 Jan 15;94(2):331-43
references: 11900219
references: Drugs. 2012 Oct 22;72(15):1953-63
references: 22994537
references: Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4
references: 7878022
references: J Biol Chem. 2005 Oct 14;280(41):34617-25
references: 16115892
references: Lancet. 2009 Mar 28;373(9669):1097-104
references: 19303137
references: Oncologist. 2012;17 (6):747-55
references: 22628056
references: Cancer Res Treat. 2011 Sep;43(3):181-8
references: 22022296
references: Cancer Res. 2010 Jan 15;70(2):666-74
references: 20068168
references: J Pathol. 2012 Jun;227(2):223-33
references: 22294416
references: JAMA. 2012 Mar 28;307(12):1265-72
references: 22453568
references: Nat Rev Cancer. 2011 Nov 17;11(12):865-78
references: 22089421
references: Lancet. 2006 Oct 14;368(9544):1329-38
references: 17046465
references: Endocr Relat Cancer. 2012 Sep 14;19(5):657-66
references: 22807497
references: Front Endocrinol (Lausanne). 2014 Feb 07;5:7
references: 24570674